A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 104 participants.

Also called NCT07318155

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 104 participants (planned count) (from the registry)
Sponsor
Sirius Therapeutics Co., Ltd. (from the registry)
Registry
  • NCT NCT07318155
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07318155. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-11 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Condition
Peripheral Arterial Disease
Intervention (Drug)
SRSD107
Intervention (Drug)
0.9 % sodium chloride
Lead sponsor
Sirius Therapeutics Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07318155
Content hash
3f1db91a64842f56c5a4c09347f769520d61d5b2aa8ced0d65e3cb5f54c7acb9